|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic alterations in pancreatic cancer显示文摘The diagnosis of pancreatic cancer is devastating for patients and their relatives as the incidence rate is approximately the same as mortality rate. Only a small percentage, which ranges from 0.4% to 4% of patients who have been given this diagnosis, will be alive at five years. At the time of diagnosis, 80% of pancreatic cancer patients have unresectable or metastatic disease. Moreover, the therapeutic alternatives offered by chemotherapy or radiotherapy are few, if not zero. For all these reasons, there is an imperative need of analyzing and understanding the primitive lesions that lead to invasive pancreatic adenocarcinoma. Molecular pathology of these lesions is the key of our understanding of the mechanisms underlying the development of this cancer and will probably help us in earlier diagnosis and better therapeutic results. This review focuses on medical research on pancreatic cancer models and the underlying genetic alterations. | Muhammad Wasif Saif Lena Karapanagiotou Kostas Syrigos | 2007 | World Journal of Gastroenterology2007，13，33： | 10 |
| 2 | Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma显示文摘Objective:Oral squamous-cell carcinoma(OSCC)accounts for >90% of oral cancers affecting adults mostly between the fourth to seventh decades of life.The most common OSCC treatment is concomitant chemoradiotherapy(CCRT)having both locoregional and distant control,but CCRT has acute and chronic toxic effects on adjacent normal tissue.This study aimed to determine the side effects of CCRT on the oral mucosa and to characterize the clinicopathology of oral lesions in patients with OSCC.Methods:This descriptive,cross-sectional study was certified by the Ethical Review Committee(UHS/Education/126-12/2728)of the University of Health Sciences,Lahore,Pakistan.OSSC patients(n=81)with various histological subtypes,grades,and stages were recruited,and findings on their oral examination were recorded.These patients received 70,90,and 119 Gy of radiotherapy dosages in combination with the chemotherapy drugs cisplatin and 5-fluorouracil.Data were analyzed using SPSS 20.0.Results:The most common presentation of OSCC was a nonhealing ulcer(63%) involving tongue(55.6%).Clinical findings included mucositis(92.6%)and xerostomia of mild,moderate,and severe degrees in 11.1%,46.9%,and 35.8% cases,respectively.Ulcers(87.7%),palpable lymph nodes(64.2%),limited mouth opening(64.2%)and fistula(40.7%) were also observed.In females,the association of radiotherapy dosage with limited mouth opening,xerostomia,and histological grading was statistically significant(P<0.05).The association of chemotherapy drugs with xerostomia(P=0.003)was also statistically significant.Conclusions:CCRT induced mucositis,xerostomia,and trismus in patients with OSCC. | Sadia Minhas Muhammad Kashif Wasif Altaf Nadeem Afzal Abdul Hanan Nagi | 2017 | Cancer Biology & Medicine2017，14，2： | 6 |
| 3 | Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer显示文摘Ziv-afilbercept(Zaltrap, Ziv) is a humanized fusion protein constructed by joining the vascular endothelial growth factor(VEGF) binding portions of human VEGF receptors 1 and 2 to the Fc portion of human immunoglobulin IgG 1. Recently, a randomized, open-label, phase Ⅲ study compared 5-fluorouracil, leucovorin, irinotecan(FOLFIRI)/Ziv with FOLFIRI/placebo in patients who had been previously treated with oxaliplatin based chemotherapy for metastatic colon cancer(mC RC). Patients who had received prior bevacizumab therapy were also eligible. This study showed that the addition of Ziv improved overall survival with median survival time of 13.5 mo vs 12.06 mo in ziv vs placebo arm. Ziv also improved progression free survival from 4.67 mo to 6.9 mo with a response rate of 19.8% in the Ziv/FOLFIRI group vs 11.1% in FOLFIRI alone group. This led to the approval of Ziv in combination with FOLFIRI in metastatic colon cancer patients treated with prior oxaliplatin regimens. The mostcommon side effects were diarrhea, stomatitis, fatigue, hypertension, weight loss, loss of appetite, abdominal pain, and headache. As the use of Ziv has become more widespread in oncology practices, familiarity with the toxicity profile of the drug and the use of practice guidelines for their treatment has become increasing important. This review will address the toxicities noted in trials using Ziv for the treatment of mC RC, and will provide recommendations for toxicity management. | Muhammad Wasif Saif Valerie Relias Kostas Syrigos Krishna S Gunturu | 2014 | World Journal of Clinical Oncology2014，5，5： | 5 |
| 4 | Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States显示文摘AIM:To assess the use of capecitabine-based therapy and associated complication rates in patients with gastroesophageal cancer(GEC)in a real-world treatment setting. METHODS:Patients with claims between 2004 and 2005 were identified from the Thomson Reuters MarketScan databases.Capecitabine regimens were compared with 5-fluorouracil(5-FU)and other chemotherapy regimens,and were stratified by treatment setting. RESULTS:We identified 1013 patients with GEC:approximately half had treatment initiated with a 5-FU regimen,whereas 11%had therapy initiated with a capecitabine regimen.The mean capecitabine dose overall was 2382±1118 mg/d,and capecitabine was used as monotherapy more often than in combination. Overall,5-FU regimens were the most common treatment option in neoadjuvant and adjuvant settings, while other non-capecitabine regimens were used more widely in first-and second-line settings.The overall unadjusted complication rate for capecitabine regimens was about half of that seen with 5-FU regimens.In multivariate analyses,capecitabine recipients had a 51%(95%CI:26%-81%)lower risk of developing any complication than 5-FU recipients did.The risk of developing bone marrow,constitutional,gastrointestinal tract,infectious,or skin complications was lowerwith capecitabine therapy than with 5-FU.CONCLUSION:Capecitabine appeared to have a favorable side effect profile compared with 5-FU,which indicates that it may be a treatment option for GEC. | Muhammad Wasif Saif Nianwen Shi Susan Zelt | 2009 | World Journal of Gastroenterology2009，15，35： | 3 |
| 5 | Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis显示文摘There are differences between African-American and white patients with colorectal cancer, concerning their characteristics before and after diagnosis. Whites are more likely to adhere to screening guidelines. This is also the case among people with positive family history. Colorectal cancer is more frequent in Blacks. Studies have shown that that since 1985, colon cancer rates have dipped 20% to 25% for Whites, while rates have gone up for African-American men and stayed the same for African-American women. Overall, African-Americans are 38% to 43% more likely to die from colon cancer than are Whites. Furthermore, it seems that there is an African-American predominance in right-sited tumors. African Americans tend to be diagnosed at a later stage, to suffer from better differentiated tumors, and to have worse prognosis when compared with Whites. Moreover, less black patients receive adjuvant chemotherapy for resectable colorectal cancer or radiation therapy for rectal cancer. Caucasians seem to respond better to standard chemotherapy regimens than AfricanAmericans. Concerning toxicity, it appears that patients of African-American descent are more likely to develop 5-FU toxicity than Whites, possibly because of their different dihydropyridine dehydrogenase status. Last but not least, screening surveillance seems to be higher among white than among black long-term colorectal cancer survivors. Socioeconomic and educational status account for most of these differences whereas little evidence exists for a genetic contribution in racial disparity. Understanding the nature of racial differences in colorectal cancer allows tailoring of screening and treatment interventions. | Anastasios Dimou Kostas N Syrigos Muhammad Wasif Saif | 2009 | World Journal of Gastroenterology2009，15，30： | 2 |
| 6 | IGF system in cancer: from bench to clinic显示文摘 | Jorge Chaves Muhammad Wasif Saif | 2011 | Anti-Cancer Drugs2011，，3： | 2 |
| 7 | Targeted therapies for pancreatic adenocarcinoma: Where do we stand, how far can we go?显示文摘Pancreatic adenocarcinoma(usually referred to aspancreatic cancer) is a highly lethal and aggressive malignancy with a disease-related mortality almost equaling its incidence, and one of the most challenging cancers to treat. The notorious resistance of pancreatic cancer not only to conventional cytotoxic therapies but also to almost all targeted agents developed to date, continues to puzzle the oncological community and represents one of the biggest hurdles to reducing the death toll from this ominous disease. This editorial highlights the most important recent advances in preclinical and clinical research, with regards to targeted therapeutics for pancreatic cancer, outlines current challenges and provides an overview of potential future perspectives in this rapidly evolving field. | Dimitra Grapsa Muhammad Wasif Saif Konstantinos Syrigos | 2015 | World Journal of Gastrointestinal Oncology2015，7，10： | 2 |
| 8 | Capecitabine: an overview of the side effects and their management显示文摘 | Muhammad Wasif Saif Nikos A. Katirtzoglou Kostas N. Syrigos | 2008 | Anti-Cancer Drugs2008，，5： | 1 |
| 9 | Dihydropyrimidine dehydrogenase deficiency in an Indian population显示文摘 | Muhammad Wasif Saif Lori Mattison Tom Carollo Hany Ezzeldin Robert B. Diasio | 2006 | Cancer Chemotherapy and Pharmacology2006，，3： | 1 |
| 10 | Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions显示文摘 | Muhammad Wasif Saif Kristin Kaley Edward Chu M. Sitki Copur | 2010 | Clinical Colorectal Cancer2010，，5： | 1 |
| 11 | Successful amelioration of oxaliplatin -induced hyperexcitabilitysyndrome with the antiepileptic pregabalin in a patientwith pancreatic cancer 显示文摘 | Muhammad Wasif Saif Shahrukh Hashmi | 2008 | Cancer Chemother Phannacol2008，61，： | 1 |
| 12 | Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer显示文摘 | Muhammad Wasif Saif Aymen Elfiky Ronald R. Salem | 2007 | Annals of Surgical Oncology2007，，6： | 1 |
| 13 | Biomass production and nutritional quality of Moringa oleifera as a field crop 显示文摘 | Nouman Wasif Siddiqui Muhammad Basra Shahzad | 2013 | Turkish Journal of Agriculture and Forestry''2013，37，： | 1 |
| 14 | An Automated and Intelligent Medical Decision Support System for Brain MRI Scans Classification 显示文摘 | Muhammad Faisal Siddiqui Ahmed Wasif Reza | 2015 | Plos One2015，，10： | 1 |
| 15 | Gastrointestinal Perforation Due to Bevacizumab in Colorectal Cancer显示文摘 | Muhammad Wasif Saif MD MBBS Aymen Elfiky MD Ronald R. Salem MB ChB | 2007 | Annals of Surgical Oncology2007，，6： | 1 |
| 16 | Capecitabine: an overview of the side effects and their management显示文摘 | Muhammad Wasif Saif Nikos A. Katirtzoglou Kostas N. Syrigos | 2008 | Anti-Cancer Drugs2008，，5： | 1 |
| 17 | Capecitabine and hand–foot syndrome显示文摘 | Muhammad Wasif Saif | 2011 | Expert Opinion on Drug Safety2011，，2： | 1 |
| 18 | Biomass production and nutritional quality of Moringa oleifera as a field crop显示文摘 | Wasif Nouman Muhammad Tahir Siddiqui Shahzad Maqsood et ol | 2013 | Turkish Journal of Agriculture and Forestry2013，37，： | 1 |
| 19 | Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer显示文摘Surgery is the only curative option for patients with liver metastases of colorectal cancer, but few patients present with resectable hepatic lesions. Chemotherapy is increasingly used to downstage initially unresectable disease and allow for potentially curative surgery. Standard chemotherapy regimens convert 10%-20% of cases to resectable disease in unselected populations and 30%-40% of those with disease confi ned to the liver. One strategy to further increase the number of candidates eligible for surgery is the addition of active targeted agents such as cetuximab and bevaci-zumab to standard chemotherapy. Data from a phase trial indicate that cetuximab increases the number of patients eligible for secondary hepatic resection,as well as the rate of complete resection when combined with first-line treatment with the FOLFIRI regimen.The safety profiles of preoperative cetuximab or bevaci-zumab have not been thoroughly assessed,but preliminary evidence indicates that these agents do not increase surgical mortality or exacerbate chemotherapy-related hepatotoxicity,such as steatosis(5-fluorouracil),steatohepatiti(irinotecan),and sinusoidal obstruction (oxaliplatin).Secondary resection is a valid treatment goal for certain patients with initially unresectable liver metastases and an important end point for future clinical trials. | Muhammad Wasif Saif | 2009 | World Journal of Gastroenterology2009，15，31： | 0 |
| 20 | BitmapAligner:Bit-Parallelism String Matching with MapReduce and Hadoop显示文摘Advancements in next-generation sequencer(NGS)platforms have improved NGS sequence data production and reduced the cost involved,which has resulted in the production of a large amount of genome data.The downstream analysis of multiple associated sequences has become a bottleneck for the growing genomic data due to storage and space utilization issues in the domain of bioinformatics.The traditional string-matching algorithms are efficient for small sized data sequences and cannot process large amounts of data for downstream analysis.This study proposes a novel bit-parallelism algorithm called BitmapAligner to overcome the issues faced due to a large number of sequences and to improve the speed and quality of multiple sequence alignment(MSA).The input files(sequences)tested over BitmapAligner can be easily managed and organized using the Hadoop distributed file system.The proposed aligner converts the test file(the whole genome sequence)into binaries of an equal length of the sequence,line by line,before the sequence alignment processing.The Hadoop distributed file system splits the larger files into blocks,based on a defined block size,which is 128 MB by default.BitmapAligner can accurately process the sequence alignment using the bitmask approach on large-scale sequences after sorting the data.The experimental results indicate that BitmapAligner operates in real time,with a large number of sequences.Moreover,BitmapAligner achieves the exact start and end positions of the pattern sequence to test the MSA application in the whole genome query sequence.The MSA’s accuracy is verified by the bitmask indexing property of the bit-parallelism extended shifts(BXS)algorithm.The dynamic and exact approach of the BXS algorithm is implemented through the MapReduce function of Apache Hadoop.Conversely,the traditional seeds-and-extend approach faces the risk of errors while identifying the pattern sequences’positions.Moreover,the proposed model resolves the largescale data challenges that are covered through MapReduce in the Hadoop framework.Hive,Yarn,HBase,Cassandra,and many other pertinent flavors are to be used in the future for data structuring and annotations on the top layer of Hadoop since Hadoop is primarily used for data organization and handles text documents. | Mary Aksa Junaid Rashid Muhammad Wasif Nisar Toqeer Mahmood Hyuk-Yoon Kwon Amir Hussain | 2021 | Computers, Materials & Continua2021，，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员